Ratifi Español Sign in
Ratifi

Federal bills from Congress.gov. State bills from Open States.

HR 430Session 2025-2026

A Resolution designating the week of May 3 through 9, 2026, as "Tardive Dyskinesia Awareness Week" in Pennsylvania.

Printer's No. PN2984

See other bills
under the
same topic PRINTER'S NO. 2984 THE GENERAL ASSEMBLY OF PENNSYLVANIAHOUSE RESOLUTION No.430 Session of 2026 INTRODUCED BY DELLOSO, HOHENSTEIN, VENKAT, HILL-EVANS, WAXMAN, RIVERA, McNEILL, FREEMAN, PROBST, SANCHEZ, BURGOS AND CEPEDA-FREYTIZ, MARCH 11, 2026 REFERRED TO COMMITTEE ON HEALTH, MARCH 11, 2026 A RESOLUTIONDesignating the week of May 3 through 9, 2026, as "Tardive Dyskinesia Awareness Week" in Pennsylvania.WHEREAS, Serious mental illnesses such as bipolar disorder, major depressive disorder and schizophrenia often require treatment with antipsychotic medications for effective management, and antipsychotic medication prescribing rates continue to rise; andWHEREAS, While prolonged use of antipsychotic medication may be essential for the treatment of certain conditions, it is associated with tardive dyskinesia (TD), a condition marked by uncontrollable, abnormal and repetitive movements of the face, torso, limbs or extremities; andWHEREAS, An individual is at higher risk of TD if the individual:(1) is 55 years of age or older, Black or a woman; or(2) has a mood disorder, substance use disorder, intellectual disability, central nervous system injury or 1234567891011121314151617 high cumulative antipsychotic medication exposure;andWHEREAS, Approximately 60% of the estimated 800,000 United States adults living with TD remain undiagnosed; andWHEREAS, Even mild TD symptoms can be stigmatizing and impair physical, social and emotional well-being, underscoring the urgency of early screening, detection and intervention; andWHEREAS, The American Psychiatric Association recommends routine TD screening in its clinical guidelines for antipsychotic treatment; andWHEREAS, Individuals treated with antipsychotic medication or experiencing abnormal movements should consult their health care providers to assess TD risk, receive TD screenings and determine appropriate treatment; andWHEREAS, Treatments approved by the United States Food and Drug Administration for TD can provide options for symptom management and an improved quality of life for many individuals living with TD; andWHEREAS, The House of Representatives encourages TD screening education and awareness for health care providers, patients and care partners to help ensure that patients who are prescribed antipsychotic medication receive care and support that aligns with clinical best practices, including regular TD screenings; therefore be itRESOLVED, That the House of Representatives designate the week of May 3 through 9, 2026, as "Tardive Dyskinesia Awareness Week" in Pennsylvania; and be it furtherRESOLVED, That the House of Representatives, in recognition and support of "Tardive Dyskinesia Awareness Week," emphasize the importance of early detection and intervention to improve 20260HR0430PN2984 - 2 - 123456789101112131415161718192021222324252627282930 outcomes for individuals living with mental health conditions and prescribed antipsychotic medication and support efforts to raise awareness about the causes and symptoms of TD and the importance of routine TD screening.20260HR0430PN2984 - 3 - 1234

Official text from the Pennsylvania Legislature. Formatting has been adapted for reading on Ratifi.